Why Growth Hormone Peptides Cause Carpal Tunnel (And How to Fix It)

Watch the full video on Rumble: https://rumble.com/v7ha5f4-why-growth-hormone-peptides-cause-carpal-tunnel-and-how-to-fix-it.html

Why Growth Hormone Peptides Cause Carpal Tunnel

Okay, so if you added ipamorelin or maybe increased your dose of tesamorelin or CJC or even added the HGH and you started to get carpal tunnel, understand that this is a normal side effect that we can expect from increased levels of HGH. Most of the time, if this happens to you, you'll see those side effects subside within about two to four weeks. It is not nerve damage and it is not a sign that something has gone wrong.

To understand why it happens you have to follow the whole chain, because the hand is the last stop, not the first one.

Ipamorelin, tesamorelin and CJC do not put growth hormone into your body. They tell your pituitary to release more of your own, and that pulse of growth hormone travels to the liver, where it gets converted into something called IGF-1, which is the hormone that does most of the actual growth signaling in tissue.

Growth hormone and IGF-1 both act on the kidney. Specifically, they push the kidney to hold onto sodium, and sodium pulls water with it, so your total body water goes up before anything else visibly changes.

Most people miss this part, since the puffiness in the hands, the tight rings, and the morning stiffness in the fingers are really a kidney story being told through soft tissue.

Bottom line is when it comes to adding growth hormone, there's changes to the way that your body manages the thermostat of hydration, keeping potassium inside of the cells, sodium outside of the cells, what that balance looks like.

As for the hand, the carpal tunnel is a narrow channel at the base of your wrist made of bone on three sides and a thick ligament across the top, and running through that channel are nine tendons and the median nerve, which is the nerve that supplies sensation to your thumb, index and middle fingers.

The roof of that channel is ligament and the floor is bone, so there is no room for it to expand, and when the tissue inside swells even slightly, the only structure soft enough to get compressed is the nerve.

Which is why the first symptom is almost never pain. It is tingling, numbness, a dead feeling in the fingers at 3am, and it is usually worse at night because you are lying flat and fluid that drained into your legs during the day redistributes upward.

The same thing happens in pregnancy, and for the same reason: fluid volume goes up, the tunnel does not.

How much fluid are we actually talking about? Not much. Moller and colleagues measured extracellular water after growth hormone administration in adults and found increases on the order of one to two liters within days, with sodium retention driving it, and that is enough to close the margin in a space that measures millimeters.

Fluid loads into the capsule around the joint the same way, and since the capsule has stretch receptors, the brain reads that stretch as a dull ache even though nothing underneath is actually being harmed.

Why it resolves on its own comes down to the kidney adapting. The renin-angiotensin-aldosterone system, which is the hormone loop that sets how much sodium you keep, gradually downregulates against the new growth hormone signal, and once your kidneys normalize, things are back where they're supposed to be, since this shift happens on its own and just takes time for your body to reacclimate to the changes in the hormones.

So the first move is usually to do nothing for two to four weeks and let the adaptation happen, while cutting back on added salt and keeping your water intake steady rather than slashing it, because dehydration does not drain the tunnel.

Most of what I know about this came out of conversations in the free community, so if you want the rest of it and somewhere to ask, the men's group is here: https://www.skool.com/jh-iron-forge-brotherhood/about

Research: Moller J, et al, on the effects of growth hormone on fluid homeostasis, published in Endocrine Reviews.